Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Open-label undersøgelse til evaluering af sikkerheden og effektiviteten af ​​CABA-201 hos forsøgspersoner med aktiv idiopatisk inflammatorisk myopati

12. november 2026 opdateret af: Cabaletta Bio

En fase 1/2, åben-label undersøgelse til evaluering af sikkerheden og effektiviteten af ​​autologe CD19-specifikke kimære antigenreceptor-T-celler (CABA-201) hos forsøgspersoner med aktiv idiopatisk inflammatorisk myopati

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

74

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • London, Det Forenede Kongerige, WC1N 3BG
        • Rekruttering
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Det Forenede Kongerige, SE5 9RS
        • Rekruttering
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Det Forenede Kongerige, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Professor Despina Eleftheriou
      • Manchester, Det Forenede Kongerige, M13 9WL
        • Rekruttering
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Det Forenede Kongerige, M6 8HD
        • Rekruttering
        • Salford Royal Hospital - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
    • California
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • University of California Irvine - Accepting Adult Patients
        • Ledende efterforsker:
          • Tahseen Mozaffar, MD
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94158
        • Rekruttering
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80046
        • Rekruttering
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Ledende efterforsker:
          • Dr. Kentaro Yomogida, MD
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Rekruttering
        • Mayo Clinic Florida - Accepting Adult Patients
        • Kontakt:
      • St. Petersburg, Florida, Forenede Stater, 33701
        • Rekruttering
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Ledende efterforsker:
          • Natalie Booth, DO
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30032
        • Rekruttering
        • Emory University - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Forenede Stater, 30029
        • Rekruttering
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Ledende efterforsker:
          • Shanmuganathan Chandrakasan, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Ledende efterforsker:
          • Dr. George Georges, MD
        • Kontakt:
      • Chicago, Illinois, Forenede Stater, 60637
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Medical Center - Accepting Adult Patients
        • Kontakt:
    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20892
        • Rekruttering
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Ledende efterforsker:
          • Susan Prockop, MD
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48105
        • Rekruttering
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55902
        • Rekruttering
        • Mayo Clinic - Accepting Adult Patients
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • David R. Fernandez, MD, PhD
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Ledende efterforsker:
          • Jae Park, MD
        • Kontakt:
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Ledende efterforsker:
          • Saira Sheikh, MD
        • Kontakt:
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Ledende efterforsker:
          • Kaveh Ardalan, MD, MS
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Oregon Health & Science University - Accepting Adult Patients
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Forenede Stater, 15261
        • Rekruttering
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Rekruttering
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Kontakt:
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
        • Rekruttering
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Ledende efterforsker:
          • Samuel John, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Houston Methodist Hospital - Accepting Adult Patients
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Ledende efterforsker:
          • Huifang (Linda) Lu, MD
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84113
        • Rekruttering
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Forenede Stater, 98105
        • Rekruttering
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Ikke rekrutterer endnu
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Ledende efterforsker:
          • Sara Sabbagh, DO
        • Kontakt:
          • Erin Hammelev - Research Coordinator
          • Telefonnummer: 414-337-7064
          • E-mail: ehammele@mcw.edu
      • Roma, Italien, 00165
        • Rekruttering
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Kontakt:
        • Ledende efterforsker:
          • Professor Franco Locatelli
      • Göttingen, Tyskland, 37075
        • Ikke rekrutterer endnu
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Kontakt:
        • Ledende efterforsker:
          • Dr. Jana Zschüntzsch

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år til 75 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navne:
  • Rese-cel
  • Resecabtagene Autoleucel
Eksperimentel: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navne:
  • Rese-cel
  • Resecabtagene Autoleucel
Eksperimentel: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Andre navne:
  • Rese-cel
  • Resecabtagene Autoleucel

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsramme: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of adverse events and laboratory abnormalities
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Tidsramme: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Tidsramme: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studiestol: Medical Director, Cabaletta Bio

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. december 2023

Primær færdiggørelse (Anslået)

1. juli 2028

Studieafslutning (Anslået)

1. juli 2028

Datoer for studieregistrering

Først indsendt

16. november 2023

Først indsendt, der opfyldte QC-kriterier

30. november 2023

Først opslået (Faktiske)

4. december 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .